Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Pheochromocytoma
Results 1-12 of 12 for your search:
Start Over
Gallium Ga 68-DOTATOC-Labeled Positron Emission Tomography in Diagnosing Disease and Response in Patients with Somatostatin Receptor-Positive Tumors
Phase: Phase II, Phase I
Type: Diagnostic
Age: 2 and over
Trial IDs: 201110718, NCI-2012-00432, 114398, 12110177, NCT01619865
A Study Evaluating Ultratrace Iobenguane I 131 (MIBG) in Patients With Malignant Pheochromocytoma/Paraganglioma
Phase: Phase II
Type: Treatment
Age: 12 and over
Trial IDs: MIP-IB12B, NCI-2010-01344, NCT00874614
Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients with Primary or Metastatic Gastrointestinal or Pancreatic Neuroendocrine Tumors
Phase: Phase II
Type: Diagnostic
Age: 18 and over
Trial IDs: 13-C-0193, NCI-2014-02318, 335154, NCT01967537
Axitinib in Treating Patients with Pheochromocytoma or Paraganglioma This is Metastatic, Recurrent or Cannot Be Removed by Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 14-C-0001, NCI-2014-02504, P11898, NCT01967576
Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Somatostatin-Receptor Positive Tumors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Diagnostic
Age: 19 and over
Trial IDs: NET0017, NCI-2014-01016, 26988, NCI-2014-00101, NCT01980732
Iobenguane I 131 in Treating Patients With Refractory Neuroblastoma or Metastatic Pheochromocytoma
Phase: No phase specified
Type: Supportive care, Treatment
Age: 1 and over
Trial IDs: 2012LS107, NCI-2013-01933, NCT01850888
Molecular Analysis in Tissue Samples From Patients With Advanced or Metastatic Neuroendocrine Tumors
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Natural history/Epidemiology
Age: 18 and over
Trial IDs: CGI-061, NCI-2013-01950, NCT02092714
Clinical Manifestations and Genetic Defects in Identifying Disease Causality in Samples From Patients with Heritable Urologic Malignant Disorders
Phase: No phase specified
Type: Genetics, Natural history/Epidemiology
Age: Not specified
Trial IDs: 89-C-0086, NCI-2013-02066, 890086, NCT00019617, NCT00001238
Cabozantinib-s-malate in Treating Patients with Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: 2014-0081, NCI-2014-02607, NCT02302833
Expanded Access Protocol Using I131-MIBG
Phase: No phase specified
Type: Treatment
Age: 12 months and over
Trial IDs: JDI2007-01, NCI-2014-01104, NCT01590680
Gallium Ga 68-edotreotide PET/CT in Diagnosing Patients with Neuroendocrine Tumors
Phase: No phase specified
Type: Diagnostic
Age: Not specified
Trial IDs: 14-226, NCI-2015-00286, NCT02358018
Start Over